AZD1480

5mg

Cat. No.: 09-B31

$100.00

AZD1480 is a potent JAK2 inhibitor that can suppress growth, survival, as well as FGFR3 and STAT3 signaling and downstream targets. AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase, and is capable of inhibiting STAT3 phosphorylation and tumor growth in a STAT3-dependent manner. This may lead to induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.

Categories: ,

Details

TECHNICAL INFORMATION

Other Names: (S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine

Chemical Formula: C14H14CIFN8

CAS Number: 935666-88-9

Molecular Weight: 348.77

Purity: >97%

IC50= JAK1=1.3nM, JAK2=.26nM

Appearance: Off-White Powder

Solubility: DMSO

 

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store  aliquots at -20°C. 

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

 

PRODUCT USE

Soluble in DMSO. Soluble at 70mg/ml

References

Derenzine | E. | et al (2011). The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 1:e46.

Loveless | M.E. | et al (2012). Comparisons of the efficacy of a JAK 1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (Cediranib) and sham treatments in mouse tumors using DCE-MRI | DW-MRI | and histology. Neoplasia. 14:54-64.

McFarland | B.C. | et al (2011). Therapeutic potential of AZD1480 for the treatment oh human glioblastoma. Mol Cancer Ther. 12:2384-93.

Tech Docs

Product Specifications

MSDS

Related products